<DOC>
	<DOCNO>NCT01866748</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerability pharmacokinetics ( effect investigate drug body ) single multiple dos long-acting GLP-1 analogue ( semaglutide ) oral formulation healthy male subject .</brief_summary>
	<brief_title>Investigation Safety , Tolerability Pharmacokinetics Single Multiple Doses Long-acting GLP-1 Analogue ( Semaglutide ) Oral Formulation Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male subject , consider generally healthy , base medical history , physical examination , result vital sign , electrocardiogram ( ECG ) laboratory safety test perform screen visit , judge investigator Body Mass Index ( BMI ) 20 30 kg/m^2 Glycosylated haemoglobin ( HbA1c ) 6.0 % ( Part B ) History , presence , cancer , diabetes clinically significant cardiovascular , respiratory , metabolic , renal , hepatic , gastrointestinal ( GI ) , endocrinological , haematological , dermatological , venereal , neurological , psychiatric disease major disorder , judge investigator Use prescription nonprescription medicinal herbal product ( except routine vitamin ) within three week precede dose . Occasional use paracetamol acetylsalicylic acid permit</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>